Longitudinal Study of Three microRNAs in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy.
Becker muscular dystrophy (BMD)
Duchenne muscular dystrophy (DMD)
biomarker
long-term follow up
microRNAs (miRs)
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2020
2020
Historique:
received:
28
01
2020
accepted:
30
03
2020
entrez:
7
5
2020
pubmed:
7
5
2020
medline:
7
5
2020
Statut:
epublish
Résumé
Our objective was to investigate the potential of three microRNAs, miR-181a-5p, miR-30c-5p, and miR-206 as prognostic biomarkers for long-term follow up of Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) patients. We analyzed the expression of three microRNAs in serum of 18 patients (DMD 13, BMD 5) and 13 controls using droplet digital PCR. Over 4 years a minimum of two and a maximum of three measurements were performed at different time points in the same patient. Correlations between microRNA serum levels, age, and functional outcome measures were analyzed. We show the individual evolution of the levels of the three microRNAs in 12 patients and also the effect of corticosteroid treatment on microRNAs expression. We measure the expression of three microRNAs in the muscle of six DMD patients and also the expression of target genes for miR-30c. We found that levels of miR-30c and miR-206 remained significantly elevated in DMD patients relative to controls over the entire study length. The introduction of the corticosteroid treatment did not significantly influence the levels of these microRNAs. We report a trend for microRNA levels to decrease with age. Moreover, miR-206 expression levels are capable to distinguish DMD from BMD patients according to ROC analysis. We found miR-30c expression decreased in the muscle of DMD patients and marked upregulation of the target genes for this microRNA. MiR-30c and miR-206 represent sensitive biomarkers for DMD, while miR-206 may have an additional value to distinguish the DMD and BMD phenotype. This may be particularly relevant to assess the effectiveness of treatments aimed at converting the DMD to the less-severe BMD like phenotype.
Identifiants
pubmed: 32373058
doi: 10.3389/fneur.2020.00304
pmc: PMC7186470
doi:
Types de publication
Journal Article
Langues
eng
Pagination
304Informations de copyright
Copyright © 2020 Trifunov, Natera-de Benito, Exposito Escudero, Ortez, Medina, Cuadras, Badosa, Carrera, Nascimento and Jimenez-Mallebrera.
Références
J Neuromuscul Dis. 2018;5(4):481-495
pubmed: 30320597
Trends Mol Med. 2017 Nov;23(11):989-1001
pubmed: 28988850
Environ Health Prev Med. 2014 Nov;19(6):452-8
pubmed: 25150707
Genomics. 1988 Jan;2(1):90-5
pubmed: 3384440
Cell Struct Funct. 2008;33(2):163-9
pubmed: 18827405
Mol Ther Nucleic Acids. 2018 Sep 7;12:283-293
pubmed: 30195767
Muscle Nerve. 2006 Aug;34(2):135-44
pubmed: 16770791
Int J Mol Sci. 2019 Sep 19;20(18):
pubmed: 31546754
Curr Genomics. 2013 Aug;14(5):330-42
pubmed: 24403852
Neuromuscul Disord. 2017 Jan;27(1):15-23
pubmed: 27979502
EBioMedicine. 2019 Jul;45:630-645
pubmed: 31257147
PLoS One. 2015 Dec 15;10(12):e0145107
pubmed: 26670220
Int J Biol Sci. 2015 Feb 05;11(3):345-52
pubmed: 25678853
PLoS One. 2013 Nov 25;8(11):e80263
pubmed: 24282529
J Neuromuscul Dis. 2015 Jul 22;2(s2):S49-S58
pubmed: 27858763
J Cachexia Sarcopenia Muscle. 2018 Aug;9(4):715-726
pubmed: 29682908
Sci Rep. 2016 Jun 21;6:28097
pubmed: 27323895
Mol Ther Nucleic Acids. 2012 Aug 14;1:e39
pubmed: 23344181
Muscle Nerve. 2010 Dec;42(6):966-74
pubmed: 21038378
J Hum Genet. 2014 Aug;59(8):454-64
pubmed: 25007885
Exp Biol Med (Maywood). 2018 Feb;243(3):283-290
pubmed: 28914096
Compr Physiol. 2016 Jun 13;6(3):1279-94
pubmed: 27347893